NCT07102901View on ClinicalTrials.gov

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Gastric CancerMetastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

SHR2554 Tablets

Oral SHR2554 tablets.

DRUG

SHR-A1811 Injection

SHR-A1811 for injection.

DRUG

SHR-A1904 Injection

SHR-A1904 for injection.

DRUG

SHR-1701 Injection

SHR-1701 injection

Trial Locations (2)

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT07102901 - Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma | Biotech Hunter | Biotech Hunter